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Abstract
Background
People with hemophilia A or B with inhibitors are at high risk of bleeding complications. Infusion of bypassing agents, such as
recombinant activated FVII (rFVIIa) and plasma-derived activated prothrombin complex concentrate, are suggested as
alternative therapies to factor VIII (haemophilia A) or IX (haemophilia B) for individuals who no longer respond to these
treatments because they develop inhibitory antibodies. The ultimate goal of treatment is to preserve the individual's joints,
otherwise destroyed by recurrent bleeds.
Objectives
To assess the effects of bypassing agent prophylaxis to prevent bleeding in people with hemophilia A or B and inhibitors.
Search methods
We searched for relevant studies from the Cystic Fibrosis and Genetic Disorders Group's Coagulopathies Trials Register,
comprising of references identified from comprehensive electronic database searches and handsearches of relevant journals
and abstract books of conference proceedings. We also searched trial registries (16 February 2017) and bibliographic
references of retrieved studies were reviewed for potential articles to be included in the review.
Date of the last search of the Cochrane Cystic Fibrosis and Genetic Disorders Coagulopathies Trials Register: 12 December
2016.
Selection criteria
We included randomized and quasi-randomized controlled studies (cross-over or parallel design) evaluating the effect of
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prophylaxis treatment with bypassing agents compared with on-demand treatment, or studies evaluating the effects of high-
dose compared with low-dose prophylaxis in males of any age with hemophilia with inhibitors.
Data collection and analysis
Two authors independently selected studies and extracted data and assessed the risk of bias according to standard
Cochrane criteria. They assessed the quality of the evidence using the GRADE criteria.
Main results
We included four randomized studies (duration 7 to 15 months) involving 116 males. Risk of bias was judged to be high in
two studies due to the open-label study design and in one study due to attrition bias.
Two studies compared on-demand treatment to prophylaxis with bypassing agents. In one study (34 males) prophylaxis
significantly reduced mean overall bleeding rates, MD - 7.27 (95% CI -9.92 to -4.62) (low quality evidence), mean number of
overall bleeding events per month, MD -1.10 (95% CI -1.54 to -0.66), mean number of hemarthrosis, MD -6.60 (95% CI -9.32
to -3.88) (low quality evidence) and mean number of joints that had hemarthrosis, MD -0.90 (95% CI -1.36 to -0.44). The
meta-analysis did not conclusively demonstrate significant benefit of prophylaxis on health-related quality of life as measured
by Haem-A-QoL score, EQ-5D total score and utility score, EQ-5D VAS and SF-36 physical summary and mental summary
score (low quality evidence for all health-related quality of life analyses).
The remaining two studies compared dose regimens. The results from one study (22 males) did not conclusively
demonstrate benefit or harm of high-dose versus low-dose recombinant activated factor VIIa (rFVIIa) as a prophylaxis for
overall bleeding rate, MD -0.82 (95% CI -2.27 to 0.63) (moderate quality evidence), target joint bleeding rate, MD -3.20 (95%
CI -7.23 to 0.83) (moderate quality evidence) and serious adverse events, RR 9.00 (95% CI, 0.54 to 149.50) (moderate
quality evidence).
The overall quality of evidence was moderate to low due to imprecision from limited information provided by studies with
small sample sizes and incomplete outcome data in one study.
Authors' conclusions
The evidence suggests that prophylaxis with bypassing agents may be effective in reducing bleeding in males with
hemophilia with inhibitors. However, there is a lack of evidence for the superiority of one agent over the other or for the
optimum dosage regimen. Further studies are needed to evaluate the benefits and harms of prophylaxis treatment on health-
related quality of life, as well as the effects of dose of bypassing agents on the outcomes.
Plain language summary
The use of bypassing agents for preventing bleeding in people with hemophilia with inhibitors
Backgound
Infusion of bypassing agents, such as recombinant activated FVII (rFVIIa) and plasma-derived activated prothrombin
complex concentrate (APCC), are suggested as alternative therapies to factor VIII (haemophilia A) or IX (haemophilia B) for
individuals who no longer respond to these treatments because they develop inhibitory antibodies. The ultimate goal of
treatment is to preserve the individual's joints, otherwise destroyed by recurrent bleeds. We therefore evaluated the
effectiveness and safety of bypassing agents when used to prevent, as compared to treat, bleeds. We also compared
different doses of bypassing agents in men with hemophilia A or B with inhibitors as a preventative (prophylactic) therapy.
Search date
The evidence is current to 12 December 2016.
Study characteristics
We searched the scientific databases for clinical studies evaluating the effects of bypassing agents in men with hemophilia A
or B with inhibitors. We included four studies (duration 7 to 15 months), involving 116 individuals. Two studies compared the
prophylactic infusion with bypassing agent to on-demand treatment (treatment given only after the bleeding occurred) and
two studies compared high-dose to low-dose preventative therapies.
Key Results
Limited evidence showed that prophylactic use of bypassing agents reduced bleeding events, joint bleeding events and
number of affected joints. There was no evidence for improved quality of life amongst those who received prophylaxis as
compared to those who received on-demand therapy. There was no evidence for a difference in benefits or harms between
high- and low-dose rFVIIa for prophylaxis.
Quality of evidence
The overall quality of evidence of these studies was moderate to low as the included studies were small and provided limited
information. Also, in one of the studies, up to 24% of the men recruited were not included in the analysis of the results, which
further increases imprecision of results.
Background 
Description of the condition
Congenital deficiency of factor (F) VIII or FIX results in the formation of alloantibodies which inhibit the activity of infused
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clotting factor concentrates (CFCs) in approximately 30% of people with severe (defined as less than 1 international unit
(IU) dL⁻¹ baseline clotting factor activity) hemophilia A (FVIII deficiency) and 2% to 5% of those with severe hemophilia B
(FIX deficiency) (Iorio 2010a).
In an analysis of the UK Haemophilia Centre Doctors' Organisation database, the cumulative risk of inhibitor formation
was 16% and 36% at five years and 75 years of age (respectively) for the 6078 males with hemophilia A and 6% and
8% (respectively) for the 1172 males with hemophilia B (Darby 2004). The rate of inhibitor formation is dependent on the
residual or baseline circulating FVIII or FIX level, being greatest in those people with severe disease (Hay 1998). Among
people with non-severe disease, those with certain mutations, particularly in the A2 and C2 domains of the F8 gene, are
more likely to develop inhibitory antibodies.
Development of inhibitors is a complex process, but likely includes factors related to the individual being treated,
the environment and the treatment provided. Patient-related or genetically determined factors include ethnicity,
race, the severity of the hemophilia, hemophilia causing mutation, major histocompatibility class, and
immunogenotype (Astermark 2010a). Environmental or non-genetic factors are ones perceived by the immune
system as danger signals (Matzinger 1994; Matzinger 2012) and may include the reason for the first infusion at a
young age and the intensity of treatment (Astermark 2010b).
Description of the intervention
Once the diagnosis of an inhibitor is made, treatment options include the management of acute bleeding, prevention
of bleeding, and immune tolerance induction (ITI), the latter being the primary treatment option (Collins 2013). One
randomized prospective trial of ITI in children with favorable risk factors has been completed (Hay 2012). Although 70% of
participants had a complete response to ITI, six of 37 participants relapsed after a median of 9.5 months. Those in whom ITI
failed or who relapsed after successful ITI, along with those in whom ITI was not attempted or those on ITI but still with
bleeding, remain at risk for bleeding and hence are candidates for prophylaxis with a bypassing agent.
Recombinant activated FVII (rFVIIa) and plasma-derived activated prothrombin complex concentrate (APCC) are
currently the only two bypassing agents available for use in people with hemophilia with inhibitors. Two randomized
trials of acute bleeding management with bypassing agents have been completed, one with rFVIIa (Young 2008)
and one with APCC (Astermark 2007) but neither involved a comparison of the prophylactic use of the two drugs. These
trials were reviewed in 2010 and superiority of one treatment over the other in terms of hemostatic control or thrombosis
risk could not be demonstrated in participants with acute bleeding (Iorio 2010b). Similarly, several non-
randomized studies failed to demonstrate superiority of one agent over the other (Chuansumrit 2000; Kavakli 2006; Lusher
1998; Pruthi 2007; Santagostino 2006; Seremetis 1994; Shapiro 1998).
Frequent bleeding, especially joint bleeding, is a common disease manifestation in people with hemophilia and
inhibitors and impacts overall health, joint health, and quality of life (Scalone 2006). Prophylaxis is the use of treatment
on a regular basis to prevent or reduce bleeding episodes. The choice of prophylactic infusion requires the medication to
be effective for bleeding management. Therefore, prophylaxis in people with hemophilia with inhibitors that do not
respond to routine factor concentrates must rely on the use of bypassing agents. In people without inhibitors, prophylaxis
is regarded as standard of care and is associated with a reduction in musculoskeletal disease burden and with a good
quality of life (Iorio 2011). However, experience with prophylaxis is limited in people with inhibitors.
In 2013, Collins recommended that prophylaxis with a bypassing agent should be considered in children with inhibitors
after the first hemarthrosis in an effort to prevent joint damage and in older people with recurrent bleeding (Collins 2013
). Regarding the choice of bypassing agent, it was recommended that this decision be individualized based on prior
response to treatment, logistics of administration and cost. In October 2013, the Medical and Scientific Advisory
Council (MASAC) of the National Hemophilia Foundation recommended that prophylaxis with bypassing agents
should be considered in people with inhibitors (MASAC 2013). No specific guidelines were provided to guide clinicians who
wished to prescribe prophylaxis.
The optimal treatment for people with hemophilia without inhibitors is the prophylactic administration of factor VIII
(hemophilia A) or factor IX (hemophilia B) concentrates (Iorio 2011). The development of neutralizing antibodies
makes treatment of bleeding with CFCs more difficult and when the concentration of the antibody is above a certain
level (≥ 5 Bethesda units dL⁻¹ (BU)), replacement therapy is no longer effective (Berntorp 2006). In these cases with
high titres of antibody, treatment with bypassing agents, either rFVIIa or APCC, is necessary to control acute
bleeding (Shapiro 2003).
Prevention of bleeding or prophylaxis in cases with high titres of antibody requires use of rFVIIa or APCC.
How the intervention might work
The development of anti-factor VIII or anti-factor IX antibodies makes the administration of substitution therapy with
factor VIII or IX (respectively) ineffective. Bypassing agents are treatments that are able to activate the coagulation
cascade independently of factor VIII and IX; thus they are unaffected by the presence of factor VIII or factor IX
inhibitors. Bypassing agents, including rFVIIa and APCC, have different mechanisms of action by which they drive
coagulation. It is known that rFVIIa activates factor Xa on an activated platelet surface or when, it is bound to tissue
factor, it can directly activate thrombin. Alternatively, APCC mainly acts by providing factors IX and X which are able
to bypass the need for FVIII to drive thrombin generation (Hedner 2000).
Prophylaxis with bypassing agents may prevent bleeding in people with hemophilia with inhibitors and specifically reduce
overall bleeding rates and joint bleeding rates without excess thrombotic and infectious risks. Ideally, prophylaxis with
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bypassing agents in people with inhibitors will ensure long-term joint protection, in the way that the prophylactic
administration of factor VIII and IX does in people without inhibitors.
Why it is important to do this review
The rationale for this review is that prophylaxis with bypassing agents may improve the quality of life for people with
hemophilia A or B with inhibitors and reduce the economic burden of treatment. This information may help to inform and
guide clinicians in decision making when managing people with congenital hemophilia and inhibitors.
Objectives 
To assess the effects of bypassing agent prophylaxis to prevent bleeding in people with hemophilia A or B and inhibitors.
Methods 
Criteria for considering studies for this review 
Types of studies 
Randomized controlled studies and quasi-randomized controlled studies (cross-over or parallel design).
Types of participants 
Males of any age with severe congenital hemophilia A or B complicated by high-responding inhibitors to FVIII or FIX,
respectively, requiring a bypassing agent as prophylaxis to control or prevent bleeding.
Types of interventions 
Prophylaxis, at any dose, any dosing frequency, and any regimen, of rFVIIa or APCC for preventing bleeding versus each
other or no prophylaxis.
Types of outcome measures 
Primary outcomes
Overall bleeding events (per month), as defined by study authors1.
Secondary outcomes
Annualised bleeding rate1.
Target joint bleeding rate2.
Annualised joint bleeding rate (AJBR)3.
Quality of life (QoL) (generic and specific validated scales including EQ-5D, Haem-A-QoL, Haemo-QoL)4.
Safety of the bypassing agents including adverse events, serious adverse events, or thromboembolic events5.
Cost and resource utilization when comparing prophylaxis to on-demand treatment regimens, including overall drug6.
utilization
Search methods for identification of studies 
There were no restrictions regarding language or publication status.
Electronic searches 
We identified relevant studies from the Cystic Fibrosis and Genetic Disorders Group's Coagulopathies Trials Register using
the terms: (Factor VIII Inhibitors) OR (factor inhibitors).
The Coagulopathies Register was compiled from electronic searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) (updated each new issue of¬The Cochrane Library), weekly searches of MEDLINE and
prospective hand-searching of one specialized journal,¬Haemophilia. Unpublished work was identified by searching the
abstract books of five major conferences: the European Haematology Association conference; the American Society of
Hematology conference; the British Society for Haematology Annual Scientific Meeting; the International Society of
Haemostasis and Thrombosis Congresses; and the International Congresses of World Federation of Haemophilia. For full
details of all searching activities for the register, please see the relevant section of the¬Cochrane Cystic Fibrosis and Genetic
Disorders Group's website.
Date of the last search of the Cochrane Cystic Fibrosis and Genetic Disorders Coagulopathies Trials Register: 12 December
2016.
We also searched trial registries such as ClinicalTrials.gov (www.clinicaltrials.gov) and the
International Clinical Trials Registry Platform (www.who.int/ictrp/en/) in an attempt to identify relevant studies for
inclusion (Appendix 1). Date of most recent search: 16 February 2017.
Searching other resources 
The bibliographic references of retrieved studies were reviewed for additional references to be included in this review.
Data collection and analysis 
Selection of studies 
Two review authors independently reviewed the abstracts from the identified articles to select those that were potentially
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eligible to be included in the review. The authors retrieved the full text reports of studies that were deemed potentially
relevant and linked together multiple reports of the same study. The authors independently examined the full text of the
studies for compliance with the eligibility criteria; and if necessary contacted the study investigators to determine study
eligibility. The authors resolved any disagreements on study inclusion by discussion in order to reach a consensus.
Data extraction and management 
A pair of authors (CC, SJN and MS) independently reviewed the identified articles and extracted data on the following (a third
author arbitrated any differences).
Inclusion criteria for the study1.
Location and timeframe of the study2.
Participant number and demographics3.
Study methods4.
Study design5.
Type, characteristics and duration of the intervention and control groups if applicable6.
Outcome measures and description7.
Information on limitations or bias (or both)8.
Assessment of risk of bias in included studies
A pair of authors (CC, SJN and MS) independently assessed the risk of bias of the included studies. The risk of bias was
assessed using Cochrane's tool for assessing the risk of bias according to the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011a). For each study, the risk of bias was noted as being either 'high risk', 'low risk', or 'unclear
risk' for the following criteria.
Sequence generation1.
Allocation concealment2.
Blinding of participant and personnel3.
Blinding of outcome assessment4.
Incomplete outcome data5.
Selected outcome reporting6.
Other issues7.
Measures of treatment effect
For the primary outcome, overall bleeding events were represented as a mean number of bleeding events per month.
Secondary outcomes of target joint bleeding events and annualised joint bleeding events were represented as a mean
number of bleeding events per month. We analyzed the data as continuous data, and reported mean differences (MD) with
the corresponding 95% confidence intervals (CIs).
For safety outcomes, i.e. adverse events related to treatment, the effect was presented as the proportion of males presenting
the event, and a risk ratio (RR). We calculated a pooled estimate of the treatment effect for each outcome using the pooled
RR and 95% CIs.
With respect to health-related quality of life (HRQoL), the mean and standard deviation (SD) of scores from scales were
presented. We calculated the mean change from baseline for each group or the mean post-intervention values and SD for
each group. We converted standard errors (SE) to SDs. We produced a pooled estimate of treatment effect by calculating
the MD and 95% CIs. If economic data are reported in updates of this review, we will analyse these data in the same way.
If for a future update, continuous scores measure the same outcome but in a variety of ways (e.g. different scales to measure
knowledge or quality of life), we plan to standardize the outcomes to a uniform scale using the standardized MD (SMD).
Where studies reported multiple measures for the same outcome, the review authors considered absolute changes in the
measure in the context of comparable data being available for each participant before and after the intervention (i.e. change
from baseline).The authors recorded continuous data, such as joint score change, as either mean change from baseline for
each group or mean post-treatment values (if change from baseline was not reported) and SD for each group.
Unit of analysis issues 
No cluster-randomized studies were identified. If cluster-randomized studies are identified for updates of the review, we will
check these studies for unit of analysis errors and perform analysis based on the advice given in chapter 16 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011b).
When conducting a meta-analysis combining results from cross-over studies, we used the methods recommended
by Elbourne (Elbourne 2002). We extracted (or calculated) MDs and SEs adjusted for the paired design of cross-over
studies. If this had not been possible, we would have considered whether data were presented by treatment period and
include only first-period data in the analysis. If neither of these options were possible, we would have included data from
cross-over studies narratively in the review.
We included one cross-over study in the review (Leissinger 2011). For the outcome of overall bleeding events, we were able
to extract individual participant data from a graph and calculate a MD and adjusted SE. We were also able to estimate that
the correlation between treatment arms was around 0.4 from these data. Therefore, we have used this correlation estimate to
adjust estimates of SE for other continuous outcomes measured in this study.
Dealing with missing data
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If reports were incomplete, we attempted to contact the original investigators in an effort to obtain the necessary data or
information. Where the original investigators could not provide additional information, we examined the proportion and
distribution of missing data (e.g. proportion of missing outcome data, demographic data, missing information regarding study
design methods etc.). We also considered, where possible, whether data were likely to be missing at random or not and
whether the missing data were likely to have had an impact on the results of the study. We judged the risk of bias due to
incomplete outcome data accordingly and performed sensitivity analyses, excluding studies with large proportions of missing
data, if appropriate.
Assessment of heterogeneity 
We assessed heterogeneity through visual examination of the combined data presented in the forest plots, and by
considering the I² statistic together with Chi² values (significance level P < 0.1) (Deeks 2011). The I² statistic reflects the
likelihood that variation of results across studies are due to heterogeneity rather than by chance, and is interpreted as
follows:
0% to 40%: might not be important;
30% to 60%: may represent moderate heterogeneity;
50% to 90%: may represent substantial heterogeneity;
75% to 100%: considerable heterogeneity.
Assessment of reporting biases
We intended to assess publication bias by constructing, then visually inspecting, the funnel plot (where a minimum of 10
studies could be included), and investigated outcome reporting bias by comparing the methods and results sections of the
published papers.
Data synthesis
Where meta-analysis could be conducted, we employed a fixed-effect model in the first instance. For future updates, when
moderate or higher heterogeneity is identified (I² of around 30% or higher), a random-effects model will be employed. For
dichotomous outcomes (adverse events related to treatment), we employed the Mantel-Haenszel method of meta-analysis
and present pooled RRs and 95% CIs. For continuous outcomes (overall bleeding events, annualised bleeding rate, target
joint bleeding events, annualised bleeding events, HRQoL, economic data, joint score change), we employed the inverse
variance method of meta-analysis and present pooled MD or SMD (as appropriate, see Measures of treatment effect) and
95% CIs.
Subgroup analysis and investigation of heterogeneity 
If we had identified moderate or higher heterogeneity (I² of around 30% or higher), we intended to investigate this by
subgroup analyses based on:
diagnosis (e.g. hemophilia A or B);1.
age of the participants (boys or adult males).2.
Sensitivity analysis
We intended to explore the impact of including studies with high levels of missing data on the overall treatment effect, if
appropriate.
Summary of findings and quality of the evidence (GRADE)
In a post hoc change from protocol, we have presented a summary of findings tables for each comparison in the
review (Summary of findings table 1; Summary of findings table 2).
The following outcomes were reported in the tables (chosen based on relevance to clinicians and consumers): overall
bleeding events; annualised bleeding rate; target joint bleeding rate; AJBR; quality of life; safety of the bypassing agents.
We determined the quality of the evidence using the GRADE approach; and downgraded evidence in the presence
of a high risk of bias in at least one study, indirectness of the evidence, unexplained heterogeneity or inconsistency,
imprecision of results, high probability of publication bias. We downgraded evidence by one level if they considered
the limitation to be serious and by two levels if very serious (Balshem 2011; Guyatt 2008).
Results 
Description of studies 
Results of the search
See Figure 1.
We identified 96 citations from the database searches. We identified a further 89 references from searches of trial
registries. Of the total 185 references, we removed three duplicates. After we reviewed the remaining titles and
abstracts, 151 were discarded as not being relevant and we retrieved the full-text references (where possible) of
nine studies (31 references). Of these, four unique studies (reported in 26 references) were eligible randomized
controlled studies and were included in the review (Antunes 2014; Konkle 2007; Leissinger 2011; Ljung 2013
). We excluded four studies (NCT02622321; NCT02795767; NCT02847637; NCT03020160) and classified
one study as awaiting further assessment (NCT01105546).
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Included studies
See Characteristics of included studies.
Four studies are included in the review (Antunes 2014; Konkle 2007; Leissinger 2011; Ljung 2013).
The Antunes study was a multicenter, parallel, randomized controlled study conducted in 17 centers (Antunes 2014).
Participants were enrolled if they were hemophilia A or B with a history of high-titre inhibitor (> 5 BU/mL) or low-titre inhibitor
(≤ 5 BU/mL) with refractory to increased dosing of factor replacement therapy. A total of 17 participants were randomized to
prophylaxis group and 19 were randomized to the on-demand therapy group. Prophylaxis regimen was nanofiltered FVIII
inhibitor bypassing activity (FEIBA NF) 85 +/- 15 units/kg bolus infusion every other day. Participants who were in the on-
demand therapy group received FEIBA NF administration when they experienced a bleeding episode, dosing depended on
type of bleeding. The study lasted for 12 months. The primary outcome was annualised bleeding rate. Secondary outcomes
were AJBR, overall bleeding events, target joint bleeding events, occurrence of new target joints, hemostatic efficacy, total
FEIBA NF utilization, safety and QoL.
The Konkle study was a multicenter, parallel, randomized controlled study conducted in 20 centers (Konkle 2007).
Participants were enrolled if they had severe hemophilia A or B with a high inhibitor titre (> 2 BU/mL), required treatment of
bleeds with a bypassing agent and had had at least four bleeds requiring hemostatic drug treatment within the previous
month prior to enrolling. There were three study periods (pre-prophylaxis, prophylaxis and post-prophylaxis). Each period
was for three consecutive months. Eleven participants were randomized to rFVIIa 270 μg/kg once daily and 11 were
randomized to rVFIIa 90 μg/kg once daily. The primary outcome was the number of bleeds per month. Secondary outcomes
were site-specific bleeding rates, safety, HRQoL and orthopedic joint scores.
The Leissinger study was a multicenter, cross-over study conducted in 16 centers (Leissinger 2011). Eligible participants
were males with severe hemophilia A and a history of high-titre inhibitor (> 5 BU/mL), who were older than two years of age,
being treated with bypassing agents and had six or more episodes of bleeding requiring treatment in the six months prior to
study enrollment. Prophylaxis regimen was anti-inhibitor coagulant complex (AICC)-FEIBA at a target dose of 85 (+/-15%)
units/kg. During the on-demand therapy period, participants received FEIBA at a dose of 85 (+/-15%) units/kg if they
experienced bleeding episodes. A total of 17 participants were randomized to prophylaxis first (six months of prophylaxis,
followed by a three-month washout period and six months of an on-demand period). A total of 17 participants were
randomized to on-demand therapy first (six months of on-demand therapy, followed by three months of washout period and
six months of prophylaxis). The primary outcome was total bleeding events (prophylaxis versus on-demand periods).
Secondary outcomes were the number of joint bleeds, the number of target joint bleeds, HRQoL and safety.
The Ljung study was a multicenter, parallel study conducted in 19 centers (Ljung 2013). Eligible participants had hemophilia
A or B with high titre inhibitor (≥ 5 BU/mL, frequent bleeds, age 12 to 65 years), had at least two bleeding episodes within the
last month or 12 bleeding episodes within the last six months prior to enrolling. There were three study periods (three months
of observation, followed by three months of prophylaxis and one month of observation). The prophylaxis regimen was 40K
glycoPEGylated recombinant FVIIa bypassing agent (N7-GP) administered at target doses of 25 μg/kg, 100 μg/kg and 200
μg/kg intravenously every second day. During the on-demand period, participants received rFVIIa for the treatment of
bleeding episodes. The primary outcome was a reduction in the annualised bleeding rate (prophylaxis versus on-demand
therapy periods). Secondary outcomes were the number of specific bleeds (stratified by sites) and causes of bleeding.
Excluded studies
We identified four studies which were excluded from the review (NCT02622321, NCT02795767, NCT02847637, 
NCT03020160) as the study drug was neither rFVIIa or APCC.
Studies awaiting assessment
We identified one study which we are currently awaiting further information on, once obtained, we will assess
this for eligibility (NCT01105546).
Risk of bias in included studies 
See Figure 2 and Figure 3. 
Allocation (selection bias)
The Antunes study used centralised stratified, block randomization (Antunes 2014), the Konkle study used centralised
computer-generated randomization (Konkle 2007) and the Leissinger study conducted the randomization and
treatment allocation by using centralized call center (telephone randomization) (Leissinger 2011). Risk of selection bias
was judged as 'low risk' of bias for these three studies. The Ljung study described that the participants were
randomized and stratified by age (Ljung 2013). There was no further information regarding random sequence generation and
allocation concealment; the risk of bias for this study was judged as 'unclear'.
Blinding (performance bias and detection bias)
Two studies were open-label and there was no information regarding the blinding of outcome assessors; therefore
the risk of bias was judged as 'high risk' (Antunes 2014; Leissinger 2011). The Konkle and Ljung studies described
the blinding procedure as providing an equal volume of trial drug to be injected in both groups (Konkle 2007; Ljung 2013).
There was no information regarding blinding of the outcome assessors; the risk of bias was judged as 'low risk' for the latter
studies.
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Incomplete outcome data (attrition bias)
The Antunes study reported that two participants withdrew from the on-demand group and one from the prophylaxis
group (Antunes 2014). The Ljung study reported that three participants withdrew during the study period (one from the
100 μg/kg group and one from the 200 μg/kg group) (Ljung 2013). There were no withdrawals during the study period
in the Konkle study (Konkle 2007). All participants were included in an intention-to-treat analysis. The participants
were well balanced across groups. The risk of bias was judged to be 'low risk' for these three studies. The
Leissinger study reported that one participant withdrew consent before receiving the study medication and a
further seven did not complete the study; the risk of bias was judged as 'high risk' for this study (Leissinger 2011).
Selective reporting (reporting bias)
All of the studies clearly specified primary and secondary outcomes. The data on all outcomes were reported. There was no
evidence of selective reporting, therefore, the risk of bias was judged to be 'low risk' for all four studies.
Other potential sources of bias
All four studies were deemed to be at 'low risk' of bias from other source of bias.
Effects of interventions 
Two comparisons were made in this review, prophylaxis compared to on-demand therapy and low-dose compared to high-
dose therapy.
Prophylaxis compared to on-demand therapy
Two studies recruiting 70 participants contributed to this comparison (Antunes 2014; Leissinger 2011). Both studies
compared prophylaxis to on-demand therapy with FEIBA (AICC or NF).
Primary outcome
1. Overall bleeding rates (per month)
One study reported on the bleeding rate per month (over a six-month period) on prophylaxis and on-demand
therapy (Leissinger 2011). At six months, prophylaxis with bypassing agent (FEIBA) significantly reduced mean
overall bleeding rates, MD -7.27 (95% CI -9.92 to -4.62) (low quality evidence) (Analysis 1.1) and the mean number
of overall bleeding per month, MD -1.10 (95% CI -1.54 to -0.66) compared with those who are on-demand group (Analysis
1.2).
Secondary outcomes
1. Annualised bleeding rates
One study reported on annualised bleeding rates; however, data were presented as median values and cannot be
entered into analysis (Antunes 2014). The median annualised bleeding rate was significantly lower among those who were
allocated to prophylaxis as compared to on-demand treatment (7.9 versus 28.7) (moderate quality evidence).
2. Joint bleeding rates
One study reported mean number of hemarthrosis (Leissinger 2011). At six months, prophylaxis with bypassing
agent (FEIBA) significantly reduced mean number of hemarthrosis, MD -6.60 (95% CI -9.32 to -3.88) when
compared to on-demand treatment (low quality evidence) (Analysis 1.3). Mean number of joint hemorrhages was
significantly lower among those who were on prophylaxis, MD -0.90 (95% CI -1.36 to -0.44) when compared to those
with on-demand therapy (Analysis 1.4).
3. AJBR
One study reported on annualised bleeding rates; however, data were presented as median values and cannot be
entered into analysis (Antunes 2014). The median AJBR was significantly lower among those who were allocated to
prophylaxis as compared to on-demand treatment (6.0 versus 22.9) (moderate-quality evidence).
4. Quality of life
Two studies reported outcome regarding to HRQoL (low-quality evidence) (Antunes 2014; Leissinger 2011). The
Antunes study evaluated HRQoL using the Haem-A-QoL, Haemo-QoL, EQ-5D, and general pain visual analog scale
(VAS) at six and 12 months (Antunes 2014). Leissinger assessed HRQoL using the EQ-5D questionnaire and the
Short-Form (SF)-36 Health survey (Leissinger 2011).
After 12 months of study, mean change from baseline of Haem-A-QoL score was not significantly different but in
favour of prophylaxis as compared with on-demand treatment, MD 3.40 (95% CI, -5.53 to 12.33) (Analysis 1.5).
Mean change from baseline of EQ-5D scores were not significantly different but in favour prophylaxis, measuring at
six months, MD 0.09 (95% CI -0.09 to 0.27) and 12 months, MD 0.07 (95% CI -0.13 to 0.27) (Analysis 1.6). Mean
change from baseline of EQ-5D VAS was not significantly different but in favour prophylaxis, measuring at six
months, MD 4.11 (95% CI, -3.66 to 11.88) and 12 months, MD 9.90 (95% CI, -5.93 to 25.73) (Analysis 1.7). Mean
change from baseline of EQ-5D utility score were not statistically different between prophylaxis and on-demand
group, MD 0.00 (95% CI -0.12 to 0.12) (Analysis 1.8). The mean change from baseline of SF36-physical summary
score was not significantly different comparing between prophylaxis and on-demand treatment at six months, MD
2.90 (95% CI -1.53 to 7.33) (Analysis 1.17). Likewise, the mean change from baseline of SF36-mental summary
score was not significantly different comparing between prophylaxis and on-demand treatment at six months, MD
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1.20 (95% CI -2.75 to 5.15) (Analysis 1.18). There were also no significant differences between the treatments for
any of the individual SF-36 physical or mental domains (Analysis 1.9; Analysis 1.10; Analysis 1.11; Analysis 1.12; Analysis
1.13; Analysis 1.14; Analysis 1.15; Analysis 1.16).
5. Safety of the bypassing agents
Two studies reported on the safety of the bypassing agents (low quality evidence) (Antunes 2014; Leissinger 2011).
Antunes reported 36 (28.8%) of treated participants in two groups experienced serious adverse effects (Antunes 2014
). No study reported thromboembolic events or major safety issues. Leissinger reported that one participant had an
allergic reaction to the study drug during prophylaxis and three participants had events related to central venous
access during prophylaxis and on-demand therapy (Leissinger 2011).
6. Cost and resource utilization
Neither study reported this outcome (Antunes 2014; Leissinger 2011)
High-dose compared to low-dose prophylaxis therapy
Two studies recruiting 46 participants contributed to this comparison (Konkle 2007; Ljung 2013). Both compared
doses of rFVIIa; Konkle compared 270 μg/kg to 90 μg/kg and Ljung compared three doses of 200 μg/kg, 100 μg/kg
and 25 μg/kg (Konkle 2007; Ljung 2013).
Primary outcome
1. Overall bleeding rate (per month)
One study reported the overall bleeding rates comparing high-dose (270 μg/kg) versus low-dose (90 μg/kg) rFVIIa (Konkle
2007). High-dose rFVIIa reduced the mean number of bleeds per month when compared to low-dose rFVIIa, but the
difference between the groups was not statistically significant, MD -0.82 (95% CI -2.27 to 0.63) (moderate quality
evidence) (Analysis 2.1).
Ljung reported the mean annualised bleeding rate per month, comparing three doses of rFVIIa (200 μg/kg, 100 μg/kg
and 25 μg/kg) (Ljung 2013). The mean annualised bleeding rates per month were reduced during prophylaxis as compared
to the on-demand treatment period for all three doses of rFVIIa. The bleeding rate could not be analysed between the groups
due to the inadequate outcome reports.
Secondary outcomes
1. Annualised bleeding rates
Ljung reported annualised bleeding among those who received three different doses of rFVIIa (Ljung 2013). As compared to
on-demand treatment period, the annualised bleeding rate during prophylaxis were reduced by 36%, 45% and 52% in
participants who received rFVIIa 200 μg/kg, 100 μg/kg and 25 μg/kg, respectively. The bleeding rate could not be analysed
between the groups due to the inadequate outcome reports.
2. Joint bleeding rate
One study reported target joint bleeding rates comparing high-dose (270 μg/kg) versus low-dose (90 μg/kg) rFVIIa (Konkle
2007). At three months, high-dose rFVIIa reduced mean joint bleeding rates when compared to low-dose rFVIIa but
the difference between the groups was not statistically significant, MD -3.20 (95% CI -7.23 to 0.83) (moderate quality
evidence) (Analysis 2.2).
3. AJBR
Neither study reported this outcome (Konkle 2007; Ljung 2013).
4. Quality of life
Neither study reported this outcome (Konkle 2007; Ljung 2013).
5. Safety of the bypassing agents
Two studies reported adverse events comparing high-dose versus low-dose rFVIIa (Ljung 2013; Konkle 2007).
There was no statistical difference of the risk of adverse events between doses, RR 1.00 (95% CI 0.57 to 1.76) for
200 μg/kg compared to 100 μg/kg, RR 1.50 (95% CI 0.67 to 3.34) for 200 μg/kg compared to 25 μg/kg, RR 1.50
(95% CI 0.67 to 3.34) for 100 μg/kg compared to 25 μg/kg and RR 0.89 (95% CI 0.56 to 1.40) for 270 μg/kg
compared to 90 μg/kg (moderate-quality evidence) (Analysis 2.3).
One study reported serious adverse events comparing high-dose versus low-dose rFVIIa (Konkle 2007). Four
participants who received high-dose rFVIIa (270 μg/kg) reported serious adverse events compared to no participants
who received low-dose (90 μg/kg). However, this difference between groups was not statistically significant, RR 9.00
(95% CI 0.54 to 149.50) (Analysis 2.4).
6. Cost and resource utilization
Neither study reported this outcome (Konkle 2007; Ljung 2013)
Discussion 
Summary of main results
Four studies were found to be eligible for the review (Antunes 2014; Konkle 2007; Leissinger 2011; Ljung 2013).
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Two studies compared prophylaxis versus on-demand treatment (Antunes 2014; Leissinger 2011) and two studies
compared high to low doses of bypassing agents for prophylaxis (Konkle 2007; Ljung 2013). The main findings of this
Cochrane Review and meta-analysis in people with hemophilia with inhibitors suggested that prophylaxis with bypassing
agents reduces overall bleeding rates and joint bleeding rates as compared to on-demand treatment. No statistically
significant differences in change from baseline for HRQoL were found and this review did not conclusively rule out benefit or
harm of high-dose compared with low-dose rFVIIa.
Overall completeness and applicability of evidence
All of the included studies enrolled people with hemophilia A or hemophilia B with inhibitors. Two studies compared
prophylaxis with on-demand treatment (Antunes 2014; Leissinger 2011). However, the remaining two studies did not
include participants who were given on-demand treatment as a control (Konkle 2007; Ljung 2013). The prophylactic
durations ranged from three months to 12 months. The data were presented differently (e.g. crude bleeding rate,
annualised bleeding rate or bleeding per month) and reported in mean or median. Consequently, meta-analyses
were prevented in some cases. Two studies evaluated HRQoL; however, the tools used in these studies varied (Antunes
2014; Leissinger 2011). Consequently, a pooled analysis could not be performed for the majority of HRQoL domains.
Although we observed statistically significant differences of the clinical outcomes regarding to the reduction of overall
bleeding rates and joint bleeding rates in those who were allocated to prophylaxis as compared to on-demand treatment, the
clinical relevance of this finding warrant further prospective studies with a greater number of participants and a longer
duration of follow-up.
Although the studies included in this review were conducted as multicenter, multinational studies; bypassing agents as a
prophylaxis in people with hemophilia with inhibitors are not widely used in countries where the resources are limited. Hence,
the applicability of this evidence to certain groups of people with hemophilia A or B is limited.
Quality of the evidence
When comparing between prophylaxis versus on-demand treatment, the quality of the evidence was moderate for outcomes
relating to annualised bleeding rates; we downgraded the evidence due to the imprecision of limited data from one or two
small studies. Other outcomes (bleeding rates, HRQoL and safety) provided low quality evidence for this comparison; in
addition to imprecision, evidence was also downgraded due to incomplete outcome data with up to 24% of participants
excluded from one cross-over study.
When comparing high-dose to low-dose rFVIIa, the quality of evidence was moderate for overall bleeding rates, target joint
bleeding rate and safety of bypassing agents; we downgraded evidence due to imprecision of limited data from one or two
small studies. Other outcomes were not reported for this comparison.
Potential biases in the review process
We performed extensive searches for this Cochrane Review. The methodology regarding study selection, data extraction,
risk of bias assessment and analyses were rigorously conducted. We contacted the corresponding authors for clarification on
data; however, there were some missing reported outcomes regarding overall bleeding rate, joint bleeding rate and health-
related outcomes. In addition, the small number of included studies in this review precluded us from conducting subgroup
analyses.
Agreements and disagreements with other studies or reviews
Valentino conducted a systematic review of six observational studies, involving 34 hemophilia people with inhibitors
who were treated with FEIBA for prophylaxis (Valentino 2010). The median prophylactic dose was 78.5 unit per kg. There
was 63.9% reduction in overall bleeding events and 73% reduction in annual joint bleeding.
Authors' conclusions 
Implications for practice 
The evidence suggests that prophylaxis with bypassing agent may be effective in people with hemophilia A or B with
inhibitors for the reduction of overall bleeding rates and joint bleeding rates (low to moderate quality evidence). There is
insufficient evidence to show that prophylaxis does affect health-related quality of life (HRQoL) as compared to on-demand
treatment (low quality evidence). There is lack of evidence of superiority of one agent over the other as well as the dosage
regimen.
Implications for research 
The small sample sizes and substantial attrition rates of the included studies limited the precision of the effect estimates.
Larger prospective studies are warranted in order to evaluate the efficacy of prophylaxis compared to on-demand treatment
and high-dose versus low-dose regimen of bypassing agents. In addition, outcome measures (such as bleeding event and
HRQoL) were non-uniformly reported. Consequently, it is difficult to compare the results across the studies and to perform
meta-analyses. Hemophilia-specific tools for assessing HRQoL may be more informative and uniform. The hemophilia
research community needs to develop a consensus on measuring and reporting outcomes in hemophilia-related literature.
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Antunes 2014
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Methods Multicenter parallel randomized study conducted in 17 centres in Bulgaria, Russia,
Croatia, Poland, Romania, USA, Japan and Brazil
 
Participants 36 males (prophylaxis (n = 17) or on-demand therapy (n = 19))
Inclusion criteria: hemophilia A or B with documented history of high-titre inhibitor (> 5
BU/mL) or low-titre inhibitor (≤ 5 BU/mL) refractory to increased dosing of either FVIII
or FIX for at least 12 months; were ≥ 4 and ≤ 65 years of age; were currently being
treated on demand with bypassing agents; had ≥ 12 bleeding episodes in the previous
12 months; and a negative HIV status, or if positive, with a stable CD4 count
Exclusion criteria: symptomatic liver disease; had platelet count < 100,000 per μL;
were currently receiving ITI or prophylaxis; needed elective surgery; needed alpha-
interferon or protease inhibitor use; or had previous thromboembolic events
 
Interventions Prophylaxis: FEIBA NF 85 +/- 15 units/kg intravenously bolus infusion every other day
On demand: FEIBA NF, dosing depended on type of bleeding and was at discretion of
the investigator
Duration of treatment: 12 months (+/- 14 days)
 
Outcomes Primary outcome: annualised bleeding rate
Secondary outcomes: AJBR, overall bleeding events, target joint bleeding events,
occurrence of new target joints, hemostatic efficacy, total FEIBA NF utilization, safety
and quality of life
 
Notes Study sponsored by Baxter Healthcare Corporation
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Block randomization in a 1:1 ratio with stratification by geography (block
size not stated)
 
Allocation concealment (selection
bias)
Low risk The randomization scheme was centralized
 
Blinding of participants and
personnel (performance bias)
High risk Open-label study
 
Blinding of outcome assessment
(detection bias)
High risk Open-label study
 
Incomplete outcome data (attrition
bias)
Low risk 2 participants withdrew from on-demand group (1 serious adverse event
and 1 surgery) and 1 from the prophylaxis group (adverse event).
Withdrawal rate similar across groups and all participants included in an
ITT analysis
 
Selective reporting (reporting bias) Low risk No protocol available. All outcomes defined in the methods reported in
the results, no evidence of selective reporting
 
Other bias Low risk None identified
 
Konkle 2007
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Methods Multicenter randomized parallel study conducted across 20 sites in Argentina, Brazil,
Bulgaria, the Philippines, Poland, Romania, Russia, South Africa, Spain, Turkey and
USA
 
Participants 22 participants (rFVIIa 270 μg/kg (n = 11) and rFVIIa 90 μg/kg (n = 11))
Inclusion criteria: males with severe congenital hemophilia A or B with a high
documented history of inhibitor titre (with an inhibitor titre > 2 BU/mL in the preceding
12 months), a requirement for current treatment of bleeds with bypassing agents, and
at least four bleeds requiring hemostatic drug treatment (except dental bleeds and
bruises) within the previous month.
Exclusion criteria: prophylaxis with any hemostatic drug within the last 3 months, ITI
within the last month, known pseudotumours, platelet count < 50,000 per μL,
advanced atherosclerotic disease, and congenital or acquired coagulation disorders
other than hemophilia A or B
 
Interventions There were 3 phases of 3-month study period (pre-prophylaxis, prophylaxis and post-
prophylaxis periods).
Prophylaxis with high dose: activated rFVIIa 270 μg/kg once daily, slow bolus
intravenously over a period of 2 minutes
Prophylaxis with low dose: rFVIIa 90 μg/kg once daily
 
Outcomes Primary outcome: number of bleeds per month comparing between during the
prophylaxis period and pre-prophylaxis period
Secondary outcomes: number of bleeds per month comparing between post-
prophylaxis period and prophylaxis period, site specific bleeding rates, safety, HRQoL,
orthopedic joint scores
 
Notes On-demand treatments of acute/breakthrough bleeds were continued as normal
practice throughout the study. 38 participants were originally recruited for the study, 37
entered the pre-treatment observation period but 15 were withdrawn
Study sponsored by Novo Nordisk
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Centralized computer-generated randomization list was used to
randomly allocate participants
 
Allocation concealment (selection
bias)
Low risk Centralized computer-generated randomization list was used to
randomly allocate participants
 
Blinding of participants and
personnel (performance bias)
Low risk Blinding was maintained by providing an equal volume of study drug to
be injected in both groups
 
Blinding of outcome assessment
(detection bias)
Unclear risk No information provided
 
Incomplete outcome data (attrition
bias)
Low risk No withdrawals during the study period. All randomized participants
analysed, ITT approach used
 
Selective reporting (reporting bias) Low risk No protocol available. All outcome defined in the methods mentioned in
the results, some outcomes reported in more detail than others (e.g. no
numerical results reported for orthopedic status)
 
Other bias Low risk None identified
 
Leissinger 2011
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Methods Multicenter randomized cross-over study conducted at 16 centres in Europe and USA
 
Participants 34 participants
Inclusion criteria: severe hemophilia A and a history of a factor VIII inhibitor titre
exceeding 5 BU, older than 2 years old, being treated with bypassing agents and had
6 or more episodes of bleeding requiring treatment in the 6 months before the study
Exclusion criteria: receiving immune tolerance therapy, regular prophylaxis with any
hemostatic agent, symptomatic liver disease, platelet count of less than 100,000 per
μL, planned elective surgery within 12 months, used an investigational product within 1
month of study enrolment, planned to begin treatment with interferon or protease
inhibitor
 
Interventions Prophylaxis: AICC (FEIBA) administration at a target dose of 85 units/kg (+/- 15%) on
3 non-consecutive days weekly
On demand: AICC at a target dose of 85 units/kg (+/- 15%) for bleeding episode
Duration of treatment: 6 months of prophylaxis, 3 months of washout period and 6
months of on-demand therapy (prophylaxis first), 6 months of on-demand therapy, 3
months of washout period and 6 months of prophylaxis (on-demand therapy first)
 
Outcomes Primary outcome: reduction of bleeding events during prophylaxis period compared
with the on-demand period
Secondary outcomes: number of joint bleeding, number of target joint bleeding,
HRQoL and safety
 
Notes Study funded by Baxter Bioscience who provided AICC. Study investigators and a
medical writer paid by Baxter Bioscience prepared the manuscript
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Randomization conducted from a centralized call center (telephone
randomization) – information from the online protocol
 
Allocation concealment (selection
bias)
Low risk Randomization conducted from a centralized call center (telephone
randomization) – information from the online protocol
 
Blinding of participants and
personnel (performance bias)
High risk For ethical and practical reasons, participants were aware of study
assignments
 
Blinding of outcome assessment
(detection bias)
High risk For ethical and practical reasons, participants were aware of study
assignments
 
Incomplete outcome data (attrition
bias)
High risk Per protocol results reported for efficacy outcomes (reduction in bleeding
rates / joint bleeding rates), ITT approach for safety outcomes (monthly
hemorrhage rates, adverse effects).
Up to 24% of participants excluded from results: 1 patient withdrew
consent before receiving study medication. The ITT group comprised 33
participants, of whom 7 did not complete the study: 1 withdrew because of
an allergic reaction, 2 died, 1 was lost to follow-up after Hurricane Katrina,
and 3 withdrew consent (2 during the on-demand period and 1 during the
prophylaxis period)
 
Selective reporting (reporting bias) Low risk Online protocol available. All outcomes reported in protocol fully reported
in the study, no evidence of selective reporting
 
Other bias Low risk None identified
 
Ljung 2013
Methods Multicenter randomized parallel study conducted over 19 sites in France, Japan,
Malaysia, Serbia, Sweden, Turkey, UK, USA, South Africa
 
Participants 24 participants (8 to each group but 1 not dosed)
Inclusion criteria: people with hemophilia A or B with high-responding inhibitors (≥ 5
BU/mL) and frequent bleeds, age 12 - 65 years, at least 2 bleeding episodes within the
last month or 12 bleeding episodes within the last 6 months
Exclusion criteria: low platelet count (< 50,000 per μL), active pseudotumours,
advanced atherosclerotic disease, severe liver disease, renal dysfunction, coagulation
disorders other than congenital hemophilia or a history of thromboembolic events
 
Interventions On-demand period: activated rFVIIa for the treatment of bleeding episodes
Prophylaxis period: 40K glycoPEGylated rFVIIa bypassing agent (N7-GP)
administration at a target doses of 25, 100 and 200 μg/kg intravenously over 2 - 5
minutes every second day
Duration of the study: 3 months of observation period (on-demand therapy), 3 months
of prophylaxis period and 1 month of observation period
 
Outcomes Primary outcome: reduction in annualised bleeding rate
Secondary outcome: number of specific bleeds stratified by sites and causes
 
Notes Study sponsored by Novo Nordisk
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Described as randomized and stratified by age, no further information
given regarding generation of random sequence
 
Allocation concealment (selection
bias)
Unclear risk No information provided
 
Blinding of participants and
personnel (performance bias)
Low risk Double-blind study: placebo solution was used to provide equal injection
volume irrespective of dose
 
Blinding of outcome assessment
(detection bias)
Unclear risk No information provided
 
Incomplete outcome data (attrition
bias)
Low risk 3 participants were withdrawn during the treatment period (1 from 100 μg
group and 2 from 200 μg group) but all were included in analyses up to
the point of withdrawal in an ITT analysis
 
Selective reporting (reporting bias) Low risk No protocol available. Most outcomes defined in the methods reported in
the results (target joint rate bleeds mentioned in the methods but not in
the results). The study is a Phase 2 dose ranging study so the main
objective of the study is safety and pharmacokinetic measures, efficacy is
a secondary measure so risk of bias is judged to be low
 
Other bias Low risk None identified
 
Footnotes
AICC: anti-inhibitor coagulant complex
AJBR: annualised joint bleeding rate
BU: Bethesda unit
FEIBA NF: nanofiltered factor eight inhibitor bypassing activity
HRQoL: health-related quality of life
ITI: immune tolerance induction
ITT: intention-to-treat
rFVIIa: recombinant factor VII
Characteristics of excluded studies 
NCT02622321
Reason for exclusion The study drug was not rFVIIa or APCC
 
NCT02795767
Reason for exclusion The study drug was not rFVIIa or APCC
 
NCT02847637
Reason for exclusion The study drug was not rFVIIa or APCC
 
NCT03020160
Reason for exclusion The study drug was not rFVIIa or APCC
 
Footnotes
APCC: activated prothrombin complex concentrate
rFVIIa: recombinant factor VIIa
Characteristics of studies awaiting classification 
NCT01105546
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Methods Multicenter parallel study in the USA, France, Germany, Italy, Romania and Spain
 
Participants Inclusion criteria: boys with hemophilia A who developed FVIII inhibitors, up to 8 years,
≤ 2 years from the time of inhibitor detection, high-responding inhibitor (≥ 5 BU/mL)
and known anamnestic response in case of negative inhibitor titre, candidate to start
ITI with FVIII concentrates (doses ranging from 50 IU/kg/day to 200 IU/kg/day), ≤ 2
bleedings in the same joint within the last 6 months before entering the study,
maximum 6 joint bleeds in the same joint within 2 years and adequate venous access
Exclusion criteria: ITI already started, sensitivity to study drug, administration of study
drug within 30 days prior randomization, family history of thrombosis at early age (< 40
years), known thrombophilia, any previous thrombosis, known pseudotumors, severe
liver disease, platelet count < 50,000 platelet/μL and surgery within 1 month or
planned for major surgery
 
Interventions On demand: on-demand treatment, treatment of bleeding episodes with rFVIIa 270
µg/kg (first/single dose) or 90 µg/kg IV every 2-3 hours until bleeding resolution
Prophylaxis: prophylaxis with rFVIIa 90 µg/kg/day
 
Outcomes No information provided
 
Notes Study sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
 
Footnotes
ITI: immune tolerance induction
IU: international units
IV: intravenous
rFVIIa: recombinant factor VIIa
Characteristics of ongoing studies 
Footnotes
Summary of findings tables
1 Prophylaxis therapy compared with on-demand therapy with FEIBA for hemophilia A or B with inhibitors
Prophylaxis therapy compared with on-demand therapy with FEIBA for hemophilia A or B with inhibitors
Population: adults and children with hemophilia A or B with inhibitors
Settings: outpatients
Intervention: prophylaxis therapy (FEIBA)
Comparison: on-demand therapy (FEIBA)
Outcomes Illustrative comparative risks* (95%
CI)
Relative
effect
(95% CI)
No of
Participants
(studies)
Quality of
the
evidence
(GRADE)
Comments
Assumed
risk
Corresponding risk
On-
demand
Prophylaxis
 
Overall bleeding
rates: total
number of
bleeding events 
Follow-up: 6
months
Not
estimable
(see
comment)
The mean total number of
bleeding events in the
prophylaxis group was
7.27 lower than the on-
demand group (9.92 lower
to 4.62 lower).
Not
estimable
(see
comment)
26
(1 study)1
 
⊕⊕⊝⊝
low2,3
 
Corresponding risk (mean
difference between groups) was
estimated taking account of the
cross-over design of the study.
Assumed risk in the on-demand
group cannot be directly
calculated.
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Annualised
bleeding rate
Follow-up: 12
months
Median
28.7 (IQR,
32.3)
The median annualised
bleeding rate was 7.9 (IQR
8.1), which was 72.5%
lower than on-demand
group.
Not
estimable
(see
comment)
34
(1 study)
 
⊕⊕⊕⊝
moderate2
Data presented as median
values and could not be entered
into analysis.
Target joint
bleeding rate:
number of
hemarthrosis
Follow-up: 6
months
Not
estimable
(see
comment)
The mean number of
hemarthrosis in the
prophylaxis group was
6.60 lower than the on-
demand group (9.32 lower
to 3.88 lower).
Not
estimable
(see
comment)
26
(1 study)1
 
⊕⊕⊝⊝
low2,3
Corresponding risk (mean
difference between groups) was
estimated taking account of the
cross-over design of the study.
Assumed risk in the on-demand
group cannot be directly
calculated.
AJBR
Follow-up: 12
months
Median
22.9 (IQR,
32.8)
The median AJBR was 6.0
(IQR 7.1), which was
73.8% lower than on-
demand group.
Not
estimable
(see
comment)
34
(1 study)
 
⊕⊕⊕⊝
moderate2
Data presented as median
values and could not be entered
into analysis.
Quality of life
Follow-up: 6 to
12 months
Not
estimable
(see
comment)
There were also no
significant differences
between the prophylaxis
and on-demand treatment
for health-related quality of
life.
Not
estimable
(see
comment)
up to 58
(2 studies)1
 
⊕⊕⊝⊝
low2,3
The health-related quality of life
was measured using Haem-A-
QoL, Haemo-QoL, EQ-5D, and
general pain visual analog scale
(VAS) and the Short-Form
(SF)-36 Health survey.
Safety of
bypassing
agents
Follow-up: 6 to
12 months
 
Not
estimable
There were no
thromboembolic event and
serious complications
reported in participants
who received treatment.
Not
estimable
(see
comment)
up to 67
(2 studies)1
 
⊕⊕⊝⊝
low2,3
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The
corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative
effect of the intervention (and its 95% CI).
AJBR: annualised joint bleeding rate; CI: confidence interval; FEIBA: factor eight inhibitor bypassing activity; IGR:
interquartile range
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
Footnotes
1. One study is of a cross-over design. 34 participants were randomized in the study but up to 24% of participants were
excluded from results.
2. Downgraded once due to imprecision; limited information available from one or two small studies.
3. Downgraded once due to risk of bias: incomplete outcome data, up to 24% of participants are excluded from analyses.
2 High-dose compared with low-dose rFVIIa for hemophilia A or B with inhibitors
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High-dose compared with low-dose rFVIIa for hemophilia A or B with inhibitors
Population: adults and children with hemophilia A or B with inhibitors
Settings: outpatients
Intervention: high-dose therapy (rFVIIa)
Comparison: low-dose therapy (rFVIIa)
Outcomes Illustrative comparative risks* (95% CI) Relative
effect
(95% CI)
No of
Participants
(studies)
Quality of
the
evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Low dose High dose
Overall
bleeding
rates: number
of bleeds per
month
Follow-up: 3
months
The mean
number of
bleeds per
month in the
low-dose group
was 2.18
The mean number of
bleeds per month in the
high-dose group was
0.82 lower than the low-
dose group (2.27 lower
to 0.63 higher).
Not
estimable
22
(1 study)
 
⊕⊕⊕⊝
moderate1
 
An additional study recruited
participants to 200 μg/kg, 100
μg/kg and 25 μg/kg. Results
showed reduction of overall
bleeding rates for all 3 groups
during prophylaxis as compared
to on-demand period. (Data could
not be entered into analysis as
SDs not presented.)
Annualised
bleeding rate
Follow-up: 3
months
Not estimable
(see comment)
Not estimable
(see comment).
Not
estimable
(see
comment)
24
(1 study)
 
NA
Results showed reduction of
overall bleeding rates for all 3
groups during prophylaxis as
compared to on-demand period.
(Data could not be entered into
analysis as SDs not presented.)
Target joint
bleeding rate
Follow-up: 3
months
The mean
number of joint
bleeds per
month in the
low-dose group
was 4.7
The mean number of
bleeds per month in the
high-dose group was
3.20 lower than the low-
dose group (7.23 lower
to 0.83 higher).
Not
estimable
22
(1 study)
 
⊕⊕⊕⊝
moderate1
 
AJBR
Follow-up: 3
months
Outcome not reported. NA  
Quality of life
Follow-up: NA
Outcome not reported. NA  
Safety of
bypassing
agents
There were no significant differences
between doses in terms of adverse
events or serious adverse events (see
comment).
Not
estimable
46
(2 studies)
 
⊕⊕⊕⊝
moderate1
Doses compared were:
270 μg/kg and 90 μg/kg
200 μg/kg and 100 μg/kg
200 μg/kg and 25 μg/kg
100 μg/kg and 25 μg/kg.
*The basis for the assumed risk is the event rate in the control group. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
AJBR: annualised joint bleeding rate; CI: confidence interval; NA: not applicable; rFVIIa: recombinant factor VIIa; SD:
standard deviation
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
Footnotes
1. Downgraded once due to imprecision; limited information available from one or two small studies.
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Data and analyses 
1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor
bypassing activity (FEIBA NF)
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
1.1 Overall bleeding rates: total
number of bleeding events 1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.1.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.2 Overall bleeding rates: number
of monthly bleeding events 1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.2.1 up to 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.3 Target joint bleeding rate:
number of hemarthroses 1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.3.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.4 Target joint bleeding rate:
number of joint hemorrhages 1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.4.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.5 Health-related QoL: change from
baseline in total Haem-A-QoL score 1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.5.1 at 12 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.6 Health-related QoL: change from
baseline in total EQ-5D score 1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.6.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.6.2 at 12 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
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1.7 Health-related QoL: change from
baseline in EQ-5D VAS score 2   Mean Difference(IV, Fixed, 95% CI) Subtotals only
   1.7.1 at 6 months 2 58 Mean Difference(IV, Fixed, 95% CI) 4.11 [-3.66, 11.88]
   1.7.2 at 12 months 1 25 Mean Difference(IV, Fixed, 95% CI) 9.90 [-5.93, 25.73]
1.8 Health-related QoL: change from
baseline in EQ-5D Utility score 1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.8.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.9 Health-related QoL: change from
baseline in SF 36 Physical
Functioning Score
1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.9.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.10 Health-related QoL: change
from baseline in SF 36 Physical
Score
1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.10.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.11 Health-related QoL: change
from baseline in SF 36 Bodily Pain
Score
1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.11.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.12 Health-related QoL: change
from baseline in SF 36 General
Health Score
1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.12.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.13 Health-related QoL: change
from baseline in SF 36 Vitality /
Energy Score
1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.13.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.14 Health-related QoL: change
from baseline in SF 36 Social
Functioning Score
1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.14.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.15 Health-related QoL: change
from baseline in SF 36 Emotional
Score
1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.15.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.16 Health-related QoL: change
from baseline in SF 36 Mental
Health Score
1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.16.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.17 Health-related QoL: change
from baseline in SF 36 Physcial
Summary Score
1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.17.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
1.18 Health-related QoL: change
from baseline in SF 36 Mental
Summary Score
1   Mean Difference(IV, Fixed, 95% CI) No totals
   1.18.1 at 6 months 1   Mean Difference(IV, Fixed, 95% CI) No totals
2 High-dose compared to low-dose recombinant factor VIIIa (rFVIIIa)
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
2.1 Overall bleeding rates: number
of bleeds per month 1   Mean Difference(IV, Fixed, 95% CI) No totals
2.2 Target joint bleeding rate:
number of joint bleeds over 3
months
1   Mean Difference(IV, Fixed, 95% CI) No totals
0179 Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
25 / 28
2.3 Number of adverse events 2   Risk Ratio(M-H, Fixed, 95% CI) No totals
   2.3.1 200 μg/kg vs 100 μg/kg 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
   2.3.2 200 μg/kg vs 25 μg/kg 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
   2.3.3 100 μg/kg vs 25 μg/kg 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
   2.3.4 270 μg/kg vs 90 μg/kg 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
2.4 Number of serious adverse
events 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
Figures
Figure 1
Caption
Study flow diagram.
Figure 2
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Caption
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included
studies.
Figure 3
Caption
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Sources of support 
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This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to
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Feedback 
Appendices 
1 Online trials databases - search strategies
Clinicaltrials.gov
Advanced Search Form
Search terms: haemophilia AND inhibitor AND prophylaxis
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Study type: Interventional Studies
WHO ICTRP
Advanced Search Form
Condition: inhibitor* AND haemophilia* OR hemophilia*
Intervention: prophyla*
[Recruitment status: ALL]
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